SCHEMBL2800713

SCHEMBL2800713

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(N)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
SOAT1 P35610 1/20 0.56
TRPV1 Q8NER1 1/20 0.54
TRPM8 Q7Z2W7 1/20 0.54
CNR1 P21554 1/20 0.53
ALDH1A1 P00352 4/20 0.51
F7 P08709 3/20 0.51
F3 P13726 3/20 0.51
PPARG P37231 2/20 0.51
PPARD Q03181 2/20 0.51
PPARA Q07869 2/20 0.51
FABP3 P05413 2/20 0.51
DUSP3 P51452 1/20 0.51
PTPN7 P35236 1/20 0.51
FFAR1 O14842 1/20 0.51
LMNA P02545 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP19A1 P11511 1/20 0.51
FABP4 P15090 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602226 0.94 MEN1 (0.53) KDM4ESOAT1TRPV1ALDH1A1FFAR1
SCHEMBL22472222 0.94 MEN1 (0.53) KDM4ESOAT1TRPV1ALDH1A1FFAR1
SCHEMBL21122072 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21122063 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21199791 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21122071 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21248646 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21248537 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21253120 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1
SCHEMBL21122062 0.85 KDM4E (0.55) KDM4ESOAT1TRPV1CNR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116835903-B Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2026-05-19 CN claimed
CN-118284419-A Methods of treating post-traumatic stress disorder 杰资制药爱尔兰有限公司 2024-07-02 CN claimed
CN-117957234-A Thienopyrrole compounds 吉利德科学公司 2024-04-30 CN claimed
CN-117120450-A Thienopyrrole compounds 吉利德科学公司 2023-11-24 CN claimed
CN-117069411-A Multi-ring structure shrinkage reducing agent, alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2023-11-17 CN claimed
CN-116835903-A Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2023-10-03 CN claimed
CN-116783202-A Thienopyrrole compounds 吉利德科学公司 2023-09-19 CN claimed
CN-116835903-B Shrinkage-reducing alkali-free liquid accelerator and preparation method thereof 陕西科之杰新材料有限公司 2026-05-19 CN disclosed
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY UNIV JOHNS HOPKINS (US) 2026-04-16 US disclosed
EP-4577247-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY The Johns Hopkins University (US) 2025-07-02 EP disclosed
EP-4003384-B1 AN EXTRACT FROM CANNABIS AND PEGANUM T C ERCIYES UNIV (TR) 2025-06-25 EP disclosed
WO-2025108106-A1 COMPOUND CONTAINING QUINOLINONE SKELETON AND USE THEREOF 中国药科大学 2025-05-30 WO disclosed
CN-119881144-A Method for extracting and detecting lipid in liquid milk raw milk 上海市质量监督检验技术研究院 2025-04-25 CN disclosed
WO-2007030697-A2 MODULATION OF NEUROGENESIS BY HDAC INHIBITION BRAINCELLS, INC. (US) 2007-03-15 WO disclosed
WO-2007025177-A2 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 WO disclosed
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 US disclosed
WO-2006133926-A1 PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS CAREX SA (FR) 2006-12-21 WO disclosed
WO-2005113600-A2 METHODS FOR THE CONTROL, TREATMENT AND MANAGEMENT OF OBESITY HAPTOGEN LTD (GB) 2005-12-01 WO disclosed
US-20040132819-A1 Appetite control method ABBOTT LABORATORIES 2004-07-08 US disclosed
WO-2004012727-A1 COMPOSITIONS COMPRISING POLYSATURATED FATTY ACID (PUFAS) FOR THE CONTROL OF APPETITE AND BODY WEIGHT MANAGEMENT ABBOTT LABORATORIES (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY CNR1, CNR2, GPR18 KDM4E 1372/4885SOAT1 2211/4885TRPV1 34/4885
US-20070049576-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 KDM4E 2095/4885SOAT1 2682/4885TRPV1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.